检索结果-南通市图书馆

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy:A Multicenter Double-Blind Randomized Controlled Trial

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2024年第3期30卷 195-202页

作者： HUANG Hao-yue lin Yu-ping WEI Hua FU Yu ZHOU Yue-hong FANG Zhao-hui QIU Xiao-tang wang mei LI Qing-bo LI shan-shan wang Shi-dong DAI Fang LIU Zhen-jie ZHAO ling WEN Jian-xuan WU Li-yan ZENG hui-yan ZHANG jin-ming LU Qi-yun HE Liu SONG Wei SUN Lu LUO Lu-lu HE Jia-li XIE Wen-wen LIANG Qing-shun HUANG Yuan ZHU sheng-ling LONG Jie-er GAO Zhi-juan WEN Ze-huai LI Chun-ji OUYANG Wen-wei LI Geng WU Ming-hui LI An-xiang HUANG jin-zhu Sanjoy K Paul TANG Xian-yu FAN Guan-jie Department of Endocrinology Guangdong Provincial Hospital of Chinese MedicineGuangzhou510120China The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou510120China Department of Endocrinology The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou510120China Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou510120China Department of Endocrinology The First Affiliated Hospital of Henan University of Chinese MedicineZhengzhou450000China Department of Endocrinology Liuyang Hospital of Chinese MedicineChangsha410000China Department of Endocrinology The First Affiliated Hospital of Anhui University of Chinese MedicineHefei230000China Department of Endocrinology Hainan Provincial Hospital of Traditional Chinese MedicineHaikou570100China Department of Endocrinology The Affiliated Hospital of Liaoning University of Traditional Chinese MedicineShenyang110000China Department of Geriatric Luoyang No.1 Hospital of Traditional Chinese MedicineLuoyangHenan Province471000China Department of Endocrinology The Second Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Department of Endocrinology Beijing University of Chinese Medicine Affiliated Dongzhimen HospitalBeijing100000China Department of Endocrinology The First Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Melbourne EpiCentre The University of Melbourne and Melbourne HealthMelbourne3013Australia

Objective:To evaluate the effect and safety of foot baths with Tangbi Waixi Decoction(TW)in treating patients with diabetic peripheral neuropathy(DPN).Methods:It is a multicenter double-blinded randomized controlled *** with DPN were recruited between November 18,2016 and May 30,2018 from 8 hospitals in *** patients received basic treatments for glycemic *** received foot baths with TW herbal granules either 66.9 g(intervention group)or 6.69 g(control group)for 30 min once a day for 2 weeks and followed by a 2-week rest,as a therapeutic *** the Toronto Clinical Scoring System total score(TCSS-TS)6 points,the patients received a total of 3 therapeutic courses(for 12 weeks)and were followed up for 12 *** primary outcome was change in TCSS-TS score at 12 and 24 *** outcomes included changes in bilateral motor nerve conduction velocity(MNCV)and sensory nerve conduction velocity(SNCV)of the median and common peroneal *** was also ***:Totally 632 patients were enrolled,and 317 and 315 were randomized to the intervention and control groups,*** the 12-week intervention,patients in both groups showed significant declines in TCSSTS scores,and significant increases in MNCV and SNCV of the median and common peroneal nerves compared with pre-treatment(P0.05),and no serious adverse event was related with ***:Treatment of TW foot baths was safe and significantly benefitted patients with DPN.A low dose of TW appeared to be more effective than a high dose.(Registry *** CTR-IOR-16009331)

关键词： diabetic peripheral neuropathy herbal medicine foot baths Chinese medicine randomized controlled trial Tangbi Waixi Decoction

在线全文

学校读者我要写书评

暂无评论

深圳市新生儿脑卒中多中心现况调查

中国当代儿科杂志 2024年第5期26卷 450-455页

作者：时莉秀冯晋兴韦艳芳路欣茹张雨茜杨林颖何胜男陈佩娟韩静陈诚涂惠英余章斌黄进洁曾淑娟陈晚铃刘颖郭燕平毛姣玉李晓东张谦慎谢治利黄梅英晏昆山应尔雅陈俊王艳荣刘亚萍宋波刘华艳肖晓冬唐红王宇娜蔡茵莎龙琦许汉强王会战孙倩韩芳张瑞彪杨传忠窦蕾时会菊王瑞蒋萍无深圳市儿童医院新生儿科广东深圳518034 深圳市宝安区妇幼保健院新生儿科广东深圳518101 深圳市龙岗区妇幼保健院/汕头大学医学院龙岗妇幼临床学院新生儿科广东深圳518172 深圳市人民医院/暨南大学第二临床医学院/南方科技大学第一附属医院新生儿科广东深圳518020 深圳市龙岗中心医院/广州中医药大学深圳临床医学院新生儿科广东深圳518116 北京大学深圳医院新生儿科广东深圳518036 华中科技大学协和深圳医院新生儿科广东深圳518052 香港大学深圳医院新生儿科广东深圳518053 深圳市龙岗区人民医院新生儿科广东深圳518172 深圳市南山区妇幼保健院新生儿科广东深圳518067 深圳市第三人民医院新生儿科广东深圳518112 深圳市龙华区中心医院新生儿科广东深圳518110 深圳市盐田区人民医院新生儿科广东深圳518081 深圳远东妇产医院新生儿科广东深圳518002 深圳市第二人民医院新生儿科广东深圳518025 陆丰市人民医院新生儿科广东陆丰516500 惠阳三和医院新生儿科广东惠州518200 惠州市第三人民医院新生儿科广东惠州516100 深圳市妇幼保健院新生儿科广东深圳518028 南方科技大学医院新生儿科广东深圳518055 深圳市罗湖区人民医院新生儿科广东深圳518005 深圳新生儿数据协作网

目的总结深圳市新生儿脑卒中发病率、临床特征及预后等情况,提高脑卒中新生儿的早期诊治能力。方法由深圳市儿童医院牵头,收集2020年1月—2022年12月深圳新生儿数据协作网组织21家单位收治的新生儿脑卒中36例,分析深圳市新生儿脑卒中发... 详细信息

目的总结深圳市新生儿脑卒中发病率、临床特征及预后等情况,提高脑卒中新生儿的早期诊治能力。方法由深圳市儿童医院牵头,收集2020年1月—2022年12月深圳新生儿数据协作网组织21家单位收治的新生儿脑卒中36例,分析深圳市新生儿脑卒中发病率、临床特征、治疗、预后等情况。结果深圳市21家医院2020、2021、2022年新生儿脑卒中的发病率分别为1/15137、1/6060、1/7704。缺血性脑卒中占75%(27/36),男性患儿占64%(23/36)。86%(31/36)的患儿在生后3d内起病,53%(19/36)以惊厥起病。颅脑影像学结果显示,22例(61%)大脑左侧发生梗死,13例(36%)基底节梗死;12例完成磁共振血管成像检查,9例(75%)累及大脑中动脉。29例患儿完成脑电图检查,21例(72%)出现尖波,10例(34%)出现电发作。不同医院对症支持治疗不同。12例(33%)完善新生儿行为神经测定评分,平均得分(32±4)分。共随访27例患儿12月龄左右的预后情况,44%(12/27)的患儿预后良好。结论新生儿脑卒中主要为缺血性脑卒中,多以惊厥为首发症状,多累及大脑中动脉,脑电图多出现尖波,神经发育评分较低,以对症支持治疗为主,部分患儿预后不良。

关键词：脑卒中多中心研究新生儿

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-Liang Li Ming-sheng Huang Wei-Zhu Yang Guo-Wen Yin Bin-Yan Zhong Jun-hui Sun Zhi-Cheng jin Jian-Jian Chen Nai-Jian Ge Wen-Bin Ding Wen-hui Li jin-Hua Huang Wei Mu shan-Zhi Gu Jia-ping Li hui Zhao Shu-Wei Wen Yan-Ming Lei Yu-sheng Song Chun-wang Yuan Wei-Dong wang Ming Huang Wei Zhao Jian-Bing Wu Song wang Xu Zhu Jian-Jun Han Wei-Xin Ren Zai-Ming Lu Wen-Ge Xing Yong Fan Hai-Lan lin Zi-Shu Zhang Guo-hui Xu Wen-Hao Hu Qiang Tu Hong-Ying Su chuan-sheng Zheng Yong Chen Xu-Ya Zhao Zhu-Ting Fang Qi wang jin-Wei Zhao Ai-Bing Xu Jian Xu Qing-Hua Wu Huan-Zhang Niu Jian wang Feng Dai Dui-ping Feng Qing-Dong Li Rong-Shu Shi Jia-Rui Li Guang Yang Hai-Bin Shi Jian-Song Ji Yu-E Liu Zheng Cai Po Yang Yang Zhao Xiao-Li Zhu Li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

Original article Efficacy and safety of Changfu peritoneal dialysis solution： a multi-center prospective randomized controlled trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第22期126卷 4204-4209页

作者： ZHOU Jian-hui NI Zhao-hui mei Chang-lin YU Xue-qing LIU Fu-you MIAO Li-ning LIU Zhi-hong YUAN Wei-jie ZHANG Ai-ping lin Hong-li CHEN Meng-hua CHEN Jiang-hua ZHANG jin-yuan HE Ya-ni CHEN Jian ZHAO Jiu-yang DING Xiao-qiang LI Ying LI Rong-shan XIE Ru-juan LIU Wen-hu XING Chang-ying wang Rong DENG Yue-yi CAO Xue-ying CAI Guang-yan MOU shan MAO Zhi-guo YANG Xiao LIU Hong SUN jing YU Yu-sheng LIU Jun SHI Shu-mei LI Long-kai TIAN Na ZHANG Xiao-hui ZHOU Wei YANG Jie ZHANG Yong SUN jing-di JI Jun ZHANG Tao YAN Yan LIU Xiao-gang wang Gang ZHANG Li ZHANG Hong LUO Jian-hua CHEN Xiang-mei Department of Nephrology State Key Laboratory of Kidney Disease Chinese People's Liberation Army General Hospital Beijing 100853 China Renal Division Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200127 China

Background A multi-center large scale study is needed to confirm the efficacy and safety of domestic peritoneal dialysis （PD） solutions. Some researchers believe that 6 Lid is enough for adequate dialysis, but there is no multi-center prospective study on Chinese population to confirm this. In this study, we evaluated the efficacy and safety of domestic PD solution （Changfu） and its difference between 6 L and 8 L dosage. Methods Adult PD patients who had taken PD therapy for at least one month were selected and divided into four groups according to two dialysis solution brands and two dialysis dosages, i.e., 6 L dose with Changfu dialysis solution, 6 L dose with Baxter dialysis solution, 8 L dose with Changfu dialysis solution, and 8 L dose with Baxter dialysis solution. After 48 weeks, the changes of primary and secondary efficacy indices were compared between different types and different dosages. We also analyzed the changes of safety indices. Results Changes of Kt/V from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of creatinine clearance rate （Ccr）. Normalized protein catabolic rate （nPCR） from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of net ultrafiltration volume （nUF） and estimated glomerular filtration rate （eGFR）. Changes of nPCR from baseline to 48 weeks between 6 L and 8 L showed no statistical differences; so did those of nUF and eGFR. The decline of Kt/V from baseline to 48 weeks in 6 L group was more than that in 8 L group. Change of Ccr was similar. During the 48-week period, the mean Kt/V was above 1.7/w, and mean Ccr was above 50 L.1.73 m-2.w1. More adverse events were found in Changfu group before Changfu Corporation commenced technology optimization, and the statistical differences disappeared after that. Conclusions The domestic PD solution （Changfu） was proven to be as effective as Baxter dialysis solution. During 48- week period, a dosage o

关键词： Changfu peritoneal dialysis solution efficacy safety

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA Yan ZHU Dong shan CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao mei HU Yun Hong HUANG jin HUANG Qiu Hua HUANG Shao Zhen JI Liang jin Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU jin ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA hui wang jing Wei SONG Fang Li SUN sheng wang Dong Ting wang Ming Xuan wang Xiao Yan wang Yin Zhen wang Yu Dong WU Wei WU Lan ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN sheng Li ZHANG Gong Qi ZHANG jin Bo ZHANG lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min wang Yan ping wang Yong Yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

基于数字图像识别和光纤传感器的直流大电流在线校准装置

在线全文

学校读者我要写书评

暂无评论

计量学报 2021年第5期42卷 623-628页

作者：梅国健王家福李传生林飞鹏董平邵海明蔡晋辉中国计量大学浙江杭州310018 浙江省计量科学研究院浙江杭州310018 中国计量科学研究院北京100029 山西省计量科学研究院山西太原030021

在电解冶金和电化学工业领域,大量霍尔直流超大电流传感器无预留校准接口。针对这一实际问题,设计了一种基于数字图像识别和光纤电流传感器的直流大电流在线校准装置。该在线校准装置以光纤电流传感器为标准,利用图像传感器实时采集霍... 详细信息

在电解冶金和电化学工业领域,大量霍尔直流超大电流传感器无预留校准接口。针对这一实际问题,设计了一种基于数字图像识别和光纤电流传感器的直流大电流在线校准装置。该在线校准装置以光纤电流传感器为标准,利用图像传感器实时采集霍尔电流传感器二次显示仪表的示数图像,对采集到的图像进行灰度化、中值滤波、二值化、闭运算、字符分割等预处理,并采用穿线法进行图像识别,获取霍尔电流传感器的采样值,并与光纤电流传感器的标准测量值进行实时比较,计算被校霍尔电流传感器的测量误差。现场校准的实验结果验证了校准方法及装置的可行性。

关键词：计量学直流大电流光纤电流传感器数字图像识别霍尔大电流传感器在线校准

基于系统层次的常见中药材生态种植模式及其配套技术

在线全文

学校读者我要写书评

暂无评论

中国中药杂志 2020年第9期45卷 1975-1981页

作者：康传志吕朝耕黄璐琦王升王红阳张文晋王瑞杉王铁霖孙嘉惠周涛郭兰萍中国中医科学院中药资源中心道地药材国家重点实验室培育基地北京100700 贵州中医药大学贵州贵阳550025

中药生态农业已成为全球生态农业中最富有活力和前景的新领域,发展中药材生态种植已成为我国中药农业的国家战略,受到了高度重视,已在全国蓬勃发展,并形成了一些较为成熟的中药材生态种植模式。该文基于系统层次从生态景观、生态系统、... 详细信息

中药生态农业已成为全球生态农业中最富有活力和前景的新领域,发展中药材生态种植已成为我国中药农业的国家战略,受到了高度重视,已在全国蓬勃发展,并形成了一些较为成熟的中药材生态种植模式。该文基于系统层次从生态景观、生态系统、生物群落、生物种群和生物个体5个层次,在梳理景观模式、循环模式、立体模式、生物多样性模式和良种良法模式等5种基本模式的基础上,总结了8种成熟的中药材生态种植技术,包括野生抚育技术、精细农业耕作技术、定向培育技术、土壤改良技术、测土配方施肥技术、菌根栽培技术、病虫草害绿色防治技术、设施栽培技术等,旨在为中药材生态种植科学研究和推广应用提供理论依据。

关键词：生态农业中药材生态种植系统层次生态种植模式

在线全文

学校读者我要写书评

暂无评论

基于区域分布的常见中药材生态种植模式

中国中药杂志 2020年第9期45卷 1982-1989页

中药生态农业作为环境友好型农业,正在全国各地如火如荼的推行。由于中药材生产对自然环境条件的依赖性很强,中药生态农业在生产实践中表现出明显的地域差异。该文收集整理了各区域较为成熟的代表性中药材生态种植模式,如药粮间套作、... 详细信息

中药生态农业作为环境友好型农业,正在全国各地如火如荼的推行。由于中药材生产对自然环境条件的依赖性很强,中药生态农业在生产实践中表现出明显的地域差异。该文收集整理了各区域较为成熟的代表性中药材生态种植模式,如药粮间套作、轮作种植模式,林下种植模式,野生抚育种植模式和景观生态种植模式等,参考《全国道地药材生产基地建设规划(2018—2025年)》和《中国中药区划》,结合生产实践,对全国8大区域的中药材生态种植模式进行系统梳理,提出了各地中药材生态种植模式有:东北地区的人参林下种植模式、华北地区的连翘仿野生种植模式、华东地区的浙贝母-水稻轮作栽培模式、华中地区的黄精林下仿野生种植模式、华南地区的阳春砂林下种植模式、西南地区的川芎-水稻水旱轮作模式、西北地区的甘草野生抚育种植模式以及青藏地区唐古特大黄仿野生种植模式等。通过梳理全国各区域常见中药材生态种植模式,以期为各分布区域内其他中药材的生态种植模式的筛选和推广应用提供参考。

关键词：道地药材生态农业中药材生态种植区域分布模式

槐杞黄颗粒辅助治疗儿童支气管哮喘疗效的真实世界研究

在线全文

学校读者我要写书评

暂无评论

中国当代儿科杂志 2021年第9期23卷 877-881页

作者：王慧敏刘传合刘长山王莹韩志英孙新陈星安淑华多力坤·木扎帕尔芦爱萍王敏程燕尹小梅刘瀚旻王红华山董丽黄英姜毅熊建新丁圣刚赵顺英王金荣黄贵民牟京辉陈育智首都儿科研究所附属儿童医院北京100020 天津医科大学第二医院天津300211 华中科技大学同济医学院附属武汉儿童医院湖北武汉430015 山西省儿童医院山西太原300013 第四军医大学第一附属医院陕西西安710000 山东省立医院山东济南250000 河北省儿童医院河北石家庄050031 新疆医科大学第一附属医院新疆乌鲁木齐830001 广东省深圳远东妇儿科医院广东深圳518001 湖北省宜昌市中心人民医院湖北宜昌443000 天津中医药大学第二附属医院天津300143 北京清华长庚医院北京102200 四川大学华西第二医院四川成都610000 北京民航总医院北京100020 安徽省儿童医院安徽合肥230022 解放军总医院第七医学中心附属八一儿童医院北京100010 重庆医科大学附属儿童医院重庆400014 武汉大学人民医院湖北武汉430060 江苏省常州市儿童医院江苏常州213000 安徽医科大学第一附属医院安徽合肥230022 首都医科大学附属北京儿童医院北京100045

目的观察槐杞黄颗粒辅助治疗儿童支气管哮喘的疗效。方法采取多中心、前瞻性、登记注册的真实世界研究方法,于全国21家医院门诊依序纳入已明确诊断支气管哮喘、年龄2~5岁、采用以下两种治疗方案之一的患儿:使用哮喘长期控制药物,即吸入... 详细信息

目的观察槐杞黄颗粒辅助治疗儿童支气管哮喘的疗效。方法采取多中心、前瞻性、登记注册的真实世界研究方法,于全国21家医院门诊依序纳入已明确诊断支气管哮喘、年龄2~5岁、采用以下两种治疗方案之一的患儿:使用哮喘长期控制药物,即吸入激素和/或白三烯受体拮抗剂,但未使用槐杞黄颗粒(控制治疗组,n=390);使用哮喘长期控制药物,同时加用槐杞黄颗粒(联合治疗组,n=1014)。收集所有患儿的个人及临床资料,于治疗后第4、8、12、20、28、36周进行门诊或电话随访。随访内容包括哮喘发作情况、鼻炎症状等,并对随访观察指标的变化进行统计学分析。结果入组前两组患儿哮喘发作次数、天数及鼻炎发作天数比较差异均无统计学意义(P>0.05)。经治疗后,联合治疗组患儿每月哮喘发作天数、重度哮喘发作次数及鼻炎发作天数均显著少于控制治疗组(P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P=0.667)。结论在使用哮喘长期控制药物治疗基础上加用槐杞黄颗粒能够改善支气管哮喘患儿的临床症状及伴发的鼻炎症状,提高哮喘控制水平,且在治疗过程中使用安全,无明显不良反应。

关键词：支气管哮喘槐杞黄颗粒辅助治疗儿童